WQZ Takes Direct Control of Medistim Stake — The Plumbing Behind a Shareholder Change

WQZ Investments, the Norwegian investment group run by shipping billionaire John Fredriksen, took a 9.9% stake in Medistim ASA around May 2026. At the same time, the company called Acapital Medi Holdco AS — which had been Medistim's largest shareholder for three years — exited the picture.

The headline reads like a change of guard. In practice, it's more like a plumbing fix. The same people who held the shares before still hold them. They just moved the shares from one corporate wrapper into another, closer to Fredriksen's main investment vehicle, as part of a multi-year cleanup that started when everything went wrong at Aeternum Capital.

The basic point is that this isn't new money or a new conviction bet. It's the same economic stake, one fewer layer of indirection between Fredriksen and Medistim. The interesting part is what that structure tells us about the kind of ownership Medistim has — and the kind of company it's become.

Medistim is a niche medical device company based in Oslo. It makes ultrasound imaging and transit-time flow measurement systems — equipment surgeons use during cardiac, vascular, and transplant operations to verify blood flow and visualize tissue. Not a growth-at-all-costs biotech pipeline. A small, profitable device business that sells into operating rooms worldwide and has been compounding steadily for over a decade.

The numbers have accelerated recently. Full-year 2025 revenue came in at around MNOK 700, up 24% year-over-year. Q2 2026 revenue hit MNOK 202, up roughly 20%, with currency-neutral organic product growth of about 34%. EBIT margins have been expanding alongside the top line. The business is doing something well: its MiraQ systems combine two functions — imaging and flow measurement — in one platform, and hospitals that adopt them tend to keep using them.

So the operating story is ordinary in the best way. A niche leader scaling a product line that surgeons actually want.

The ownership story is less ordinary, which is why the May 2026 disclosure drew attention.

Here's the chain. Aeternum Capital was founded in 2020 as a Norwegian investment firm. John Fredriksen — whose WQZ Investment Group manages investments across shipping, oil trading, and a basket of Norwegian equities — was its largest backer. Aeternum bought into Medistim in 2022, acquiring about 1.9 million shares from Salvesen & Thams Invest for NOK 246 per share, bringing it to roughly 10% of the company.

Then, in 2023, Fredriksen pulled most of his capital out of Aeternum. The relationship soured enough to end up in court. To unwind the situation, Aeternum transferred those 1.9 million Medistim shares to a newly created holding company called Acapital Medi Holdco AS — a so-called in-specie redemption. That's just a fancy way of saying instead of returning cash to the investor, the fund gave the investor the actual underlying asset. Acapital Medi Holdco became the disclosed Medistim shareholder, and Fredriksen (through WQZ) sat behind it.

That arrangement worked. Erik Rogstad, who represents Acapital on Medistim's board, has been there through the intervening years. Acapital Medi Holdco's position grew to about 2.3 million shares by Q1 2026, probably through small open-market purchases and share count reductions from Medistim's buyback program.

Now, the May 2026 disclosure shows WQZ Investment Group stepping into direct ownership of roughly 9.9% of Medistim, while Acapital Medi Holdco exits. Other Acapital holdco entities for different investments have been dissolved in recent months — Acapital Elimp Holdco AS was deregistered in February 2026. The pattern is straightforward: Fredriksen is folding these single-stock holding companies back into his main investment group, removing an intermediate layer that existed because of a specific 2023 fund-restructuring situation.

Investor: We thought we bought a clean 10% stake in Medistim through Aeternum. Fredriksen: Sure. But when the fund went sideways, you got the shares in kind, sitting inside a holdco nobody else uses. (Three years later) Fredriksen: Actually, let's just move them to the main vehicle. Fewer companies to file.

Does this matter for Medistim as an investment?

The economic answer is no — not directly. The shares haven't changed hands between unrelated parties. No one is dumping a position or making a fresh bet. The voting power, the board representation, the economic exposure — it's all the same, just registered under a slightly different legal name.

But the structural answer is mildly informative. What it tells you is that Medistim's ownership is concentrated and patient. About 46% of the company is held by its top shareholders, with WQZ/Aeternum at roughly 10%, Odin Forvaltning at roughly another 10%, and other institutional and family holdings filling the rest. Fredriksen has been connected to Medistim since 2022 through the Aeternum channel, and this restructure makes the connection cleaner rather than weaker.

That's neither bullish nor bearish on its own. A stable 10% block means fewer shares circulating in the open market and one fewer potential seller. It also means the company has at least one major shareholder who sits on the board and thinks in years, not trading windows. For a small-cap Norwegian medical device company that doesn't trade on any major U.S. exchange, that kind of ownership structure reduces some of the friction and volatility you'd get if the float were dominated by short-term funds.

The real question for anyone looking at Medistim has nothing to do with the holdco shuffle and everything to do with the operating trajectory. The company is growing revenue in the low-to-mid 20s percentage, expanding EBIT margins, and operating in a niche where its combined-function device has genuine differentiation. The stock trades at around NOK 258 per share (as of late August 2026), with a market cap of roughly MNOK 4,700 — that's about $440 million at current exchange rates. Valuation for a profitable niche device company growing that fast is not cheap, but it's not absurd either.

The restructure tells you who's sitting in the building with the shares. The earnings tell you whether the building is worth owning. The plumbing is settled. The economics are what you should be watching.